

Clinical Trial Protocol

Iranian Registry of Clinical Trials

07 Jun 2026

Effect of Omega-3 therapy on the serum level of Homocysteine in peritoneal dialysis patients

Protocol summary

Study aim

The aim of this study is to investigate several parameters related to oxidative stress and systemic inflammation, especially homocysteine in peritoneal dialysis patients receiving omega-3 fatty acids.

Design

A concealed, randomized, blinded, sham-controlled clinical trial with a parallel-group design of 100 patients, block randomization was used for randomization.

Settings and conduct

Individuals who meet the inclusion criteria will be randomly assigned to the intervention and control groups. Demographic and clinical characteristics of patients will be recorded. Patients in the omega-3 soft capsule intervention group will receive one gram with each meal for 8 weeks. Participants in the control group will receive a placebo. Serum lipid profile, serum albumin level, ESR level, hs-CRP level and serum homocysteine level were measured in all patients before the start of the study and after 8 weeks at the end of the study. Finally, using statistical tests, the average of the measured tests will be compared between the two groups. Researchers and patients are blinded

Participants/Inclusion and exclusion criteria

Inclusion criteria: age 18 years and older, ESRD patients undergoing peritoneal dialysis, informed consent to participate in this study Exclusion criteria: history of malignancy, patients with a history of known allergies to products containing omega-3, coagulation disorders and use of anticoagulants, use of any antioxidant or anti-inflammatory drugs, severe systemic diseases or infectious diseases

Intervention groups

For the intervention group omega-3 capsules (120 mg DHA plus 180 mg EPA) at a dose of 3000 mg per day, ie 1000 mg with each meal per day for 8 weeks will be prescribed and the control group will receive a placebo.

Main outcome variables

Homocysteine levels and inflammatory and oxidative

markers

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20160713028901N2**

Registration date: **2020-09-07, 1399/06/17**

Registration timing: **prospective**

Last update: **2020-09-07, 1399/06/17**

Update count: **0**

Registration date

2020-09-07, 1399/06/17

Registrant information

Name

Shirinsadat Badri

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 31 3792 7068

Email address

badri@pharm.mui.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2020-09-22, 1399/07/01

Expected recruitment end date

2021-06-22, 1400/04/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Effect of Omega-3 therapy on the serum level of Homocysteine in peritoneal dialysis patients

Public title

The effect of omega-3 on the serum level of homocysteine in peritoneal dialysis patients

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

At least 18 years old ESRD patients undergoing peritoneal dialysis Informed consent to participate in this study

Exclusion criteria:

Age

From **18 years** old

Gender

Both

Phase

2-3

Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser

Sample size

Target sample size: **100**

Randomization (investigator's opinion)

Randomized

Randomization description

In this study, the basis of randomization of samples will be based on the Blocked randomization method. Information such as the number of treatment groups (the two main intervention groups, for example, A and placebo, for example, B), the size of the blocks (a multiple of the number of groups that will be selected in this study to reduce the complexity of size 4 work) and the total number of patients (Enter the sample size of 100 people) into the Internet software for this calculation (for example, available at <https://www.sealedenvelope.com/simple-randomiser/v1/lits>) and according to the codes with the final analysis is obtained, a code is assigned to each patient who enters the study, and the type of group that should take medication or placebo will be determined. Blocking is usually used to balance the number of samples assigned to each of the groups studied. In this method, equal blocking will be used. In this way, the samples are randomized as much as possible in both groups. At the end of the sampling, the code of each patient is opened and matched with the software output, and as far as possible, the data collector and intervener try to be informed of the drug code information only after analyzing the data.

Blinding (investigator's opinion)

Double blinded

Blinding description

Due to the nature of soft gelatin, preparation of placebo related to omega-3 capsules cannot be done in Isfahan School of Pharmacy and will be done in coordination with Zahravi Company in that factory. According to the company's pharmaceutical experts, edible vegetable oils that do not contain linoleic acid are used to make placebo. Also, the main omega-3 product containing each capsule (EPA equivalent of 180 mg and equivalent of 120 mg) is prepared from the same factory so that the drug and placebo are in the same package and the blinding method can be performed well. Then a small number of placebo and supplement products for a patient, provided they complete the entire course with a dose of three times a day and a special code, are provided to the student. The information in this special code on drug packages is only available to the main executor of the project who is not involved in the sampling, and the rest of the project partners do not know if the relevant code is for the drug or placebo. Thus, sampling will be done by the blind method.

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Isfahan university of medical sciences

Street address

Hezar-Jerib street

City

Isfahan

Province

Isfahan

Postal code

Approval date

2020-09-04, 1399/06/14

Ethics committee reference number

IR.MUI.MED.REC.1399.458

Health conditions studied

1

Description of health condition studied

Peritoneal dialysis

ICD-10 code

Z49.2

ICD-10 code description

Other dialysis

Primary outcomes

1

Description

Homocysteine levels and inflammatory and oxidative factors

Timepoint

Before the start and at the end of week 8

Method of measurement

Homocysteine measurement kit; Other parameters will be measured according to the laboratory standard

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: Omega-3 capsules (120 mg DHA plus 180 mg EPA) at a dose of 3000 mg per day, ie 1000 mg with each meal per day for 8 weeks

Category

Treatment - Drugs

2

Description

Control group: Placebo, with each meal for 8 weeks

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Al-Zahra University Hospital

Full name of responsible person

Shirinsadat Badri

Street address

Soffe Blvd

City

Isfahan

Province

Isfahan

Postal code

8174675731

Phone

+98 31 3620 2020

Email

alzahra@mui.ac.ir

Web page address

http://alzahra.mui.ac.ir

2

Recruitment center

Name of recruitment center

Isfahan Noor Hospital

Full name of responsible person

Shirinsadat Badri

Street address

Intersection of Hasht Behesht Street and Governor Street

City

Isfahan

Province

Isfahan

Postal code

.

Phone

+98 31 3222 2127

Email

nour@mui.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Esfahan University of Medical Sciences

Full name of responsible person

Dr. Shaghayegh Haghjoi Javanmard

Street address

Vice Chancellery of Research, Isfahan University of Medical Scienc

City

Isfahan

Province

Isfahan

Postal code

Phone

+98 31 3668 8138

Email

research@mui.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Esfahan University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Esfahan University of Medical Sciences

Full name of responsible person

Shirinsadat Badri

Position

Assistant Professor

Latest degree

Specialist

Other areas of specialty/work

Medical Pharmacy

Street address

Department of Clinical Pharmacy, School of Pharmacy, Isfahan University of Medical Sciences

City

Isfahan

Province

Isfahan

Postal code

Phone

+98 31 3792 7068

Email

badri@pharm.mui.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity

Esfahan University of Medical Sciences

Full name of responsible person

Shirinsadat Badri

Position

Assistant Professor

Latest degree

Specialist

Other areas of specialty/work

Medical Pharmacy

Street address

Department of Clinical Pharmacy, School of Pharmacy, Isfahan University of Medical Sciences

City

Isfahan

Province

Isfahan

Postal code

Phone

+98 31 3792 7068

Email

badri@pharm.mui.ac.ir

Person responsible for updating data

Contact

Name of organization / entity

Esfahan University of Medical Sciences

Full name of responsible person

Shirinsadat Badri

Position

Assistant Professor

Latest degree

Specialist

Other areas of specialty/work

Medical Pharmacy

Street address

Department of Clinical Pharmacy, School of Pharmacy, Isfahan University of Medical Sciences

City

Isfahan

Province

Isfahan

Postal code

Phone

+98 31 3792 7069

Email

badri@pharm.mui.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD

Confidentiality of information

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

No - There is not a plan to make this available

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

No - There is not a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

No - There is not a plan to make this available